Does the media refer more to ADCT or ANAB?

In the previous week, ADC Therapeutics and ADC Therapeutics both had 2 articles in the media. AnaptysBio's average media sentiment score of 1.31 beat ADC Therapeutics' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADCT or CAPR?

In the previous week, Capricor Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Capricor Therapeutics and 2 mentions for ADC Therapeutics. Capricor Therapeutics' average media sentiment score of 0.12 beat ADC Therapeutics' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer AGIO or ADCT?

In the previous week, Agios Pharmaceuticals had 12 more articles in the media than ADC Therapeutics. MarketBeat recorded 14 mentions for Agios Pharmaceuticals and 2 mentions for ADC Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.37 beat ADC Therapeutics' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADCT or CMPS?

In the previous week, Compass Pathways had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Compass Pathways and 2 mentions for ADC Therapeutics. Compass Pathways' average media sentiment score of 0.47 beat ADC Therapeutics' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ADCT or PVLA?

In the previous week, Palvella Therapeutics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Palvella Therapeutics and 2 mentions for ADC Therapeutics. Palvella Therapeutics' average media sentiment score of 0.84 beat ADC Therapeutics' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADC Therapeutics (ADCT) Competitors

$3.07 -0.10 (-3.25%)

Closing price 03:58 PM Eastern

Extended Trading

$1.76 -1.31 (-42.78%)

As of 07:17 PM Eastern

Compare

ADCT vs. ANAB, CAPR, AGIO, CMPS, and PVLA

Should you buy ADC Therapeutics stock or one of its competitors? MarketBeat compares ADC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADC Therapeutics include AnaptysBio (ANAB), Capricor Therapeutics (CAPR), Agios Pharmaceuticals (AGIO), Compass Pathways (CMPS), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry.

How does ADC Therapeutics compare to AnaptysBio?

ADC Therapeutics (NYSE:ADCT) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

ADC Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 160.84%. AnaptysBio has a consensus target price of $79.18, indicating a potential upside of 54.53%. Given ADC Therapeutics' higher possible upside, equities analysts plainly believe ADC Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
AnaptysBio	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

AnaptysBio has a net margin of -11.53% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
AnaptysBio	-11.53%	-1,101.24%	-7.75%

ADC Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

41.1% of ADC Therapeutics shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by insiders. Comparatively, 33.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

AnaptysBio has higher revenue and earnings than ADC Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	4.79	-$142.62M	-$1.05	N/A
AnaptysBio	$234.60M	6.36	-$13.23M	-$1.08	N/A

In the previous week, ADC Therapeutics and ADC Therapeutics both had 2 articles in the media. AnaptysBio's average media sentiment score of 1.31 beat ADC Therapeutics' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AnaptysBio beats ADC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Capricor Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Capricor Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	4.79	-$142.62M	-$1.05	N/A
Capricor Therapeutics	$22.27M	71.87	-$105.04M	-$2.32	N/A

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ADC Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 160.84%. Capricor Therapeutics has a consensus target price of $48.36, suggesting a potential upside of 74.98%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Capricor Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Capricor Therapeutics	N/A	-59.27%	-48.65%

In the previous week, Capricor Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Capricor Therapeutics and 2 mentions for ADC Therapeutics. Capricor Therapeutics' average media sentiment score of 0.12 beat ADC Therapeutics' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ADC Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Summary

ADC Therapeutics and Capricor Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Agios Pharmaceuticals currently has a consensus price target of $41.44, suggesting a potential upside of 49.86%. ADC Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 160.84%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ADC Therapeutics has a net margin of -173.02% compared to Agios Pharmaceuticals' net margin of -639.84%. ADC Therapeutics' return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
ADC Therapeutics	-173.02%	N/A	-44.70%

ADC Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$66.05M	24.90	-$412.78M	-$7.25	N/A
ADC Therapeutics	$81.36M	4.79	-$142.62M	-$1.05	N/A

Agios Pharmaceuticals has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 12 more articles in the media than ADC Therapeutics. MarketBeat recorded 14 mentions for Agios Pharmaceuticals and 2 mentions for ADC Therapeutics. Agios Pharmaceuticals' average media sentiment score of 0.37 beat ADC Therapeutics' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.1% of ADC Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ADC Therapeutics beats Agios Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does ADC Therapeutics compare to Compass Pathways?

ADC Therapeutics (NYSE:ADCT) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

ADC Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 160.84%. Compass Pathways has a consensus target price of $21.36, suggesting a potential upside of 68.35%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

ADC Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Compass Pathways has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Compass Pathways	N/A	-31.07%	-11.40%

ADC Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	4.79	-$142.62M	-$1.05	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

In the previous week, Compass Pathways had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Compass Pathways and 2 mentions for ADC Therapeutics. Compass Pathways' average media sentiment score of 0.47 beat ADC Therapeutics' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compass Pathways beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Palvella Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Palvella Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Palvella Therapeutics	N/A	-56.87%	-42.50%

ADC Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Palvella Therapeutics and 2 mentions for ADC Therapeutics. Palvella Therapeutics' average media sentiment score of 0.84 beat ADC Therapeutics' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	4.79	-$142.62M	-$1.05	N/A
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A

ADC Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 160.84%. Palvella Therapeutics has a consensus price target of $199.53, suggesting a potential upside of 72.88%. Given ADC Therapeutics' higher probable upside, equities analysts clearly believe ADC Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Summary

Palvella Therapeutics beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$390.09M	$3.28B	$6.45B	$23.08B
Dividend Yield	N/A	2.33%	2.69%	4.09%
P/E Ratio	-2.92	17.93	22.30	31.02
Price / Sales	4.79	324.62	581.44	14.81
Price / Cash	N/A	116.27	42.31	24.78
Price / Book	-2.04	6.63	9.84	4.67
Net Income	-$142.62M	$24.20M	$3.57B	$1.07B
7 Day Performance	-10.71%	-3.24%	-1.16%	-0.67%
1 Month Performance	-20.03%	0.53%	3.85%	0.22%
1 Year Performance	-14.69%	47.24%	27.40%	25.44%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	2.3099 of 5 stars	$3.07 -3.2%	$8.00 +160.8%	-9.6%	$390.09M	$81.36M	N/A	310	News Coverage
ANAB AnaptysBio	3.0449 of 5 stars	$58.63 -1.8%	$79.18 +35.1%	+134.5%	$1.71B	$234.60M	N/A	100	Positive News
CAPR Capricor Therapeutics	2.5764 of 5 stars	$29.29 +1.5%	$48.36 +65.1%	+167.8%	$1.70B	$22.27M	N/A	101
AGIO Agios Pharmaceuticals	2.511 of 5 stars	$28.02 -0.4%	$41.56 +48.3%	-18.8%	$1.67B	$54.03M	N/A	390	Analyst Revision
CMPS Compass Pathways	3.2204 of 5 stars	$12.30 +4.1%	$20.58 +67.3%	+205.0%	$1.66B	N/A	N/A	120	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. ANAB, CAPR, AGIO, CMPS, and PVLA

How does ADC Therapeutics compare to AnaptysBio?

Summary

How does ADC Therapeutics compare to Capricor Therapeutics?

Summary

How does ADC Therapeutics compare to Agios Pharmaceuticals?

Summary

How does ADC Therapeutics compare to Compass Pathways?

Summary

How does ADC Therapeutics compare to Palvella Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. ANAB, CAPR, AGIO, CMPS, and PVLA

How does ADC Therapeutics compare to AnaptysBio?

Do analysts rate ADCT or ANAB?

Is ADCT or ANAB more profitable?

Which has more volatility and risk, ADCT or ANAB?

Do insiders & institutionals believe in ADCT or ANAB?

Which has better valuation and earnings, ADCT or ANAB?

Does the media refer more to ADCT or ANAB?

Summary

How does ADC Therapeutics compare to Capricor Therapeutics?

Which has better valuation and earnings, ADCT or CAPR?

Do institutionals and insiders hold more shares of ADCT or CAPR?

Do analysts recommend ADCT or CAPR?

Is ADCT or CAPR more profitable?

Does the media favor ADCT or CAPR?

Which has more volatility & risk, ADCT or CAPR?

Summary

How does ADC Therapeutics compare to Agios Pharmaceuticals?

Do analysts prefer AGIO or ADCT?

Is AGIO or ADCT more profitable?

Which has better earnings and valuation, AGIO or ADCT?

Which has more risk & volatility, AGIO or ADCT?

Does the media prefer AGIO or ADCT?

Do institutionals & insiders hold more shares of AGIO or ADCT?

Summary

How does ADC Therapeutics compare to Compass Pathways?

Do analysts prefer ADCT or CMPS?

Which has more volatility & risk, ADCT or CMPS?

Do institutionals and insiders hold more shares of ADCT or CMPS?

Is ADCT or CMPS more profitable?

Which has higher valuation and earnings, ADCT or CMPS?

Does the media prefer ADCT or CMPS?

Summary

How does ADC Therapeutics compare to Palvella Therapeutics?

Do insiders and institutionals hold more shares of ADCT or PVLA?

Is ADCT or PVLA more profitable?

Which has more volatility and risk, ADCT or PVLA?

Does the media favor ADCT or PVLA?

Which has preferable earnings & valuation, ADCT or PVLA?

Do analysts rate ADCT or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools